Early acute hepatitis with parenteral amiodarone: a toxic effect of the vehicle?

A Rhodes, J B Eastwood, S A Smith

Abstract
A 72 year old white man developed acute hepatic impairment and renal failure within 24 hours of starting intravenous amiodarone for paroxysmal ventricular tachycardia. After normal initial investigations, there was a noticeable rise in serum transaminases as well as an increase in clotting times, a decrease in renal function and a thrombocytopenia. These changes returned to normal within seven days of withdrawal of the drug without specific treatment, and the patient was later treated with oral amiodarone without any further evidence of hepatotoxicity. Intravenous amiodarone has been implicated in acute hepatic disease on four previous occasions, but it is suggested that polysorbate 80, an organic surfactant added to the intravenous infusion, is a more likely cause of this complication. Similar reactions have been described with polysorbate 80 in association with the ‘E-ferol’ syndrome in infants. The occurrence of acute hepatic impairment with intravenous amiodarone does not necessarily preclude the use of this drug by mouth.

(Gut 1993; 34: 565–566)

A 72 year old man with ischaemic heart disease and poor ventricular function was admitted to hospital after collapsing at home. He had previously had three vessel coronary bypass grafts in 1977 and then had a myocardial infarction after cardiac catheterisation for unstable angina in April 1991.

At the time of admission he was in mild congestive cardiac failure, with a mildly raised jugular venous pressure at 3 cm but no other evidence of oedema, ascites, or hepatomegaly. His electrocardiogram showed sinus rhythm with widespread ST-T wave abnormalities. He was on long term treatment with frusemide (80 mg twice a day), enalapril (10 mg once a day), isosorbide mononitrate (10 mg once a day), and aspirin (150 mg once a day). These drugs had not been changed over the previous three months. During the first 24 hours in hospital, he had three sustained episodes of ventricular tachycardia, at a rate of 200 per minute, associated with circulatory collapse and syncope. All three episodes were self terminating after 1–4 minutes. He was started on intravenous amiodarone at a rate of 300 mg over the first hour followed by 900 mg over the next 24 hours.

The results of initial laboratory investigations were normal for hepatic, renal (Table), and thyroid function but there was mild hypokalaemia for which supplementation was started with Sando-K (two tablets three times a day). Within 12 hours of starting the intravenous amiodarone the liver function tests were noticeably abnormal and he had developed signs of hepatic encephalopathy (grade 1). He became oliguric with increases in creatinine and urea.

There was a neutrophil leucocytosis with appreciable derangement of the clotting times. He subsequently became thrombocytopenic with hypokalaemia and hypocalcaemia.

A toxic hepatitis was suspected and the amiodarone was stopped after 24 hours. The hepatitis and the renal failure were treated conservatively. Fresh frozen plasma was given to correct the clotting. Within 48 hours there was a symptomatic improvement and the chemical and haematological abnormalities had begun to improve.

At day 7 oral amiodarone (200 mg three times daily) was reintroduced with no adverse effects.

The liver function continued to improve. There was no recurrence of his ventricular tachycardias.

Patient’s biochemical and haematological parameters over the course of the hospital admission*

<table>
<thead>
<tr>
<th>Day</th>
<th>Treatment</th>
<th>C (μmol/l)</th>
<th>B (μmol/l)</th>
<th>ALT U/I</th>
<th>AST U/I</th>
<th>LDH U/I</th>
<th>PLT (x10^3/l)</th>
<th>PT (s)</th>
<th>WT (kg)</th>
<th>Urine (vol/ml)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Admitted</td>
<td>134</td>
<td>21</td>
<td>69</td>
<td>50</td>
<td>167</td>
<td>70</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>Amiodarone iv</td>
<td>140</td>
<td>27</td>
<td>84</td>
<td>59</td>
<td>192</td>
<td>72</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>Amiodarone iv</td>
<td>272</td>
<td>71</td>
<td>4642</td>
<td>5236</td>
<td>9262</td>
<td>34</td>
<td>150</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>No treatment</td>
<td>328</td>
<td>63</td>
<td>7238</td>
<td>6204</td>
<td>147</td>
<td>35</td>
<td>1015</td>
<td></td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>No treatment</td>
<td>264</td>
<td></td>
<td>98</td>
<td>25</td>
<td>72</td>
<td>170</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6</td>
<td>No treatment</td>
<td>74</td>
<td></td>
<td>92</td>
<td>14</td>
<td>71</td>
<td>3000</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7</td>
<td>No treatment</td>
<td>152</td>
<td>64</td>
<td>2695</td>
<td>357</td>
<td>220</td>
<td>106</td>
<td>3850</td>
<td></td>
<td></td>
</tr>
<tr>
<td>8</td>
<td>No treatment</td>
<td>113</td>
<td>50</td>
<td>1915</td>
<td>196</td>
<td>177</td>
<td>124</td>
<td>69</td>
<td>4450</td>
<td></td>
</tr>
<tr>
<td>9</td>
<td>Amiodarone po</td>
<td>112</td>
<td>36</td>
<td>1360</td>
<td>113</td>
<td>145</td>
<td>3000</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10</td>
<td>Amiodarone po</td>
<td>120</td>
<td>33</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11</td>
<td>Amiodarone po</td>
<td>145</td>
<td>23</td>
<td>478</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12</td>
<td>Amiodarone po</td>
<td>155</td>
<td>19</td>
<td>322</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13</td>
<td>Amiodarone po</td>
<td>152</td>
<td>20</td>
<td>289</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14</td>
<td>Amiodarone po</td>
<td>145</td>
<td>19</td>
<td>175</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*ALT=alanine aminotransferase; AST=aspartate aminotransferase; LDH=lactate dehydrogenase; PLT=platelet count; PT=prothrombin time; WT=weight; Urine=volume of urine in 24 hours.

Doses of amiodarone, iv; 500 mg over 1 hour followed by 900 mg over 24 hours: amiodarone, po; 200 mg three times a day.
while he remained in hospital. The patient was discharged home 17 days after admission with no further arrhythmias or biochemical dysfunction.

He went home feeling better than he had done for some time but he died suddenly during sleep three days later, presumably from a breakthrough cardiac arrhythmia. All other drugs, with the exception of Sando-K had continued unchanged throughout.

Discussion
Amiodarone is an iodinated benzo furane derivative which is used in a wide variety of cardiac arrhythmias resistant to other treatments. It has a long half life and may be administered either orally or intravenously. It has the benefit of having no negative inotropic properties.

The drug has many extracardiac side effects, including corneal microdeposits, photosensitivity, and hypothermicity. Some 15–40% of patients taking it long term develop an asymptomatic hepatic dysfunction, which is both dose dependent and reversible on stopping treatment.

A similar biochemical picture to this may be seen with severe heart failure. It is unlikely, however, that the rises seen in the alanine aminotransferase, aspartate aminotransferase, and lactate dehydrogenase activities in this patient have anything other than hepatic cause. The biochemical test to prove this would have been the differentiating between the cardiac and the hepatic lactate dehydrogenase isoenzymes. Unfortunately, these were not available.

Severe acute hepatitis immediately after intravenous amiodarone has been reported four times.** Never before, however, has oral amiodarone been reintroduced after this type of reaction. As oral amiodarone had no adverse effect on the liver function in our patient, we suggest that it may have been one of the other constituents of the intravenous solution which was responsible for the hepatotoxicity.

In order to obtain stable solutions of amiodarone for intravenous use, the drug is dissolved in a mixture of polysorbate 80 (polyoxyethylated sorbitan ester) a small amount of benzyl alcohol, and water. Polysorbate 80 has been implicated in the E-ferol syndrome which has been described in infants.7

The E-ferol syndrome is characterised by hepatomegaly, splenomegaly, cholestatic jaundice, renal failure, and thrombocytopenia. It is associated with the use of an intravenous preparation of vitamin E, E-ferol, which contains polysorbate 80 and polysorbate 20. The liver histology in this syndrome shows Kupffer cell exfoliation, centrilobular accumulation of cellular debris, and panlobular congestion, especially in central areas. The polysorbates are deemed responsible for these changes. The clinical features of the E-ferol syndrome show noticeable similarities to those found in our cases of acute hepatitis after intravenous amiodarone and similar cases described by others.

Although this particular adverse reaction of intravenous amiodarone is rare, it remains important because of the popularity of amiodarone for the treatment of severe life threatening cardiac arrhythmias.

Amiodarone, with its lack of negative inotropic, broad spectrum of action, and high efficacy is the only drug of its kind available for use in life threatening arrhythmias in patients with severe left ventricular impairment. We feel that the occurrence of acute hepatitis with the intravenous preparation does not necessarily preclude the subsequent use of the oral preparation in these patients. We would advocate caution, however, and recommend careful monitoring of hepatic and renal parameters.

This case has been reported to the Committee of Safety of Medicines.

Early acute hepatitis with parenteral amiodarone: a toxic effect of the vehicle?

A Rhodes, J B Eastwood and S A Smith

Gut 1993 34: 565-566
doi: 10.1136/gut.34.4.565

Updated information and services can be found at:
http://gut.bmj.com/content/34/4/565

These include:

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/